If you invested in ImmunityBio, Inc. (NASDAQ: IBRX) stock, the critical deadline to file as a lead plaintiff in the ongoing securities class action is May 26, 2026. This date is not optional—it’s the firm legal deadline set by the court, and missing it means you cannot play an active role in shaping the lawsuit even if you remain part of the class.
The deadline applies to investors who purchased or acquired ImmunityBio public securities and want to take a leadership position in the case, which stems from the company’s handling of its Anktiva drug after the FDA issued a warning letter on March 13, 2026, citing misbranding violations in advertisements. The case emerged after the FDA’s warning letter became public on March 24, 2026—causing ImmunityBio’s stock to plunge 21% in immediate market reaction. The class action alleges violations of the Securities Exchange Act of 1934 by ImmunityBio and its Executive Chairman/CEO Richard Adcock. This article explains what the lead plaintiff deadline means, who is eligible to participate, what actions you need to take by May 26, and what happens after that date passes.
Table of Contents
- What Triggered the ImmunityBio Securities Class Action?
- Understanding the FDA’s Regulatory Action and Its Consequences
- Who Is Eligible to Participate in the Class Action?
- What Does the May 26, 2026 Lead Plaintiff Deadline Mean?
- Why the Lead Plaintiff Deadline Matters More Than You Think
- How to File as Lead Plaintiff by May 26, 2026
- What Happens After the Lead Plaintiff Deadline Passes?
What Triggered the ImmunityBio Securities Class Action?
The securities lawsuit centers on ImmunityBio’s marketing of Anktiva, a drug product that became the subject of regulatory scrutiny when the FDA issued a warning letter on March 13, 2026. According to the FDA’s communication, the company ran advertisements (a television ad and podcast) that misbranded Anktiva and violated the Federal Food, Drug, and Cosmetic Act. Misbranding in the FDA’s context means the drug was promoted in ways that made unsupported or misleading claims about its safety or efficacy.
When news of the FDA warning letter spread on March 24, 2026, investors reacted sharply—ImmunityBio’s stock price fell 21% in response. This sharp decline is the central allegation: that ImmunityBio and its leadership failed to disclose material risks related to the company’s marketing practices and regulatory compliance before the FDA action became public. For investors who held shares during this period, the sudden stock price drop represented real financial losses. The lawsuit argues that if investors had known about the FDA’s concerns earlier, they would not have held or purchased the stock at the inflated pre-disclosure prices.
Understanding the FDA’s Regulatory Action and Its Consequences
The FDA’s warning letter is not merely a slap on the wrist—it represents a formal regulatory enforcement action that flags serious compliance failures. When the FDA issues a warning letter about drug advertising, it signals that the company has crossed legal boundaries in how it promotes a medication to the public. In this case, the misbranding allegations suggest that ImmunityBio’s TV and podcast advertisements overstated or misrepresented Anktiva’s benefits or downplayed its risks, in violation of federal drug advertising law. However, it’s important to understand that FDA warning letters don’t automatically result in criminal charges or criminal liability for executives.
The regulatory enforcement is civil in nature—the FDA tells the company it violated the law and typically demands corrective action. But from a securities law perspective, the situation is different: investors argue that ImmunityBio’s leadership should have known about the marketing problems and disclosed them as a material risk factor. If the company was running advertisements it knew (or should have known) the FDA would challenge, that’s information investors deserved to have. The 21% stock decline suggests that investors did not have this information and were misled about the company’s regulatory standing.
Who Is Eligible to Participate in the Class Action?
The class action is open to any investor who purchased or acquired ImmunityBio public securities during the class period. The precise start and end dates of the class period will be defined in the complaint and court documents, but typically it runs from the point when the company allegedly began making misleading statements or failing to disclose material facts, through the date the truth became public (March 24, 2026, when the FDA warning letter’s significance was widely reported).
Eligible investors include those who bought shares on the open market through a brokerage account, employees who received restricted stock or options, and anyone else who held ImmunityBio securities during the relevant period. You do not need to have sold your shares at a loss to be eligible—the class action protects investors who were harmed by holding shares that declined in value because of the undisclosed or misrepresented information. If you purchased shares at $10 and they dropped to $8 after the FDA warning became public, you have a claim for the difference (plus legal fees will be deducted from any settlement or judgment).
What Does the May 26, 2026 Lead Plaintiff Deadline Mean?
The May 26, 2026 deadline is specifically for investors who want to serve as “lead plaintiff”—the representative shareholder who will be the named party in the lawsuit and help direct the case. Being a lead plaintiff is different from being a class member. Every investor in the class benefits from any settlement or judgment, whether or not they filed paperwork. However, only lead plaintiffs have a formal voice in approving settlements, choosing counsel, and making strategic decisions about the litigation.
If you file a declaration or motion to be considered as lead plaintiff by May 26, 2026, you’re asking the court to appoint you (or your group of investors) to represent all shareholders in the class. The court will typically appoint the plaintiff(s) with the largest financial stake in the outcome, as they have the strongest incentive to see the case through. This process is called the “lead plaintiff selection” or “PSLRA appointment process” (named after the Private Securities Litigation Reform Act). If you do not file by May 26, you remain a class member but cannot hold the lead plaintiff position.
Why the Lead Plaintiff Deadline Matters More Than You Think
Many investors assume all deadlines in a class action are equally important, but the lead plaintiff deadline is truly critical—it’s earlier and more restrictive than other deadlines that come later. After May 26, 2026, the class still exists and other investors can still join, but only the appointed lead plaintiff(s) will have formal authority in the case. This matters because the lead plaintiff and their counsel drive strategic decisions: whether to settle, for how much, and on what terms. In class actions, there can be tension between what’s best for the largest shareholders (lead plaintiffs) and what’s best for smaller shareholders (class members).
For instance, a lead plaintiff might agree to a settlement that recovers 30 cents per share if it’s spread across many shares held, but a smaller investor might have preferred to continue fighting for 50 cents per share even with more risk. While courts and securities law try to prevent unfair settlements, having your voice heard in the process is valuable. Additionally, if you are appointed lead plaintiff, you may be entitled to a “lead plaintiff service award”—typically a modest sum (ranging from $5,000 to $30,000 or more, depending on case size) for your time and effort. This is separate from your pro-rata share of any recovery.
How to File as Lead Plaintiff by May 26, 2026
The mechanics of filing as lead plaintiff involve submitting a formal declaration to the court and the law firms handling the case. The law firms representing the class—Rosen Law Firm (the first filing firm) and Robbins Geller Rudman & Dowd LLP—can provide you with the specific forms and instructions. You’ll need to detail your investment in ImmunityBio securities, the dates you purchased and sold (if applicable), the amount of money you invested and lost, and any other relevant holdings. The declaration is a sworn statement under penalty of perjury, so accuracy is essential.
You’ll also need to show that you’re an adequate representative of the class—meaning your interests align with other investors and you’re willing to be the public face of the lawsuit. Once you file, the court will review all lead plaintiff candidates and appoint the one(s) deemed most adequate. If multiple investors have similar investment amounts, the court may appoint a group or choose the one with the earliest investment date. After May 26, this opportunity closes for new applicants.
What Happens After the Lead Plaintiff Deadline Passes?
After May 26, 2026, the court will review the filings and appoint lead plaintiff(s) within a specific timeframe (often 60 days or so after the deadline). Once appointed, the lead plaintiff and their counsel will move forward with the litigation, which typically involves exchanging evidence, taking depositions, and negotiating settlement discussions. The class itself remains open; investors who did not file for lead plaintiff status can still join the class and benefit from any recovery, they simply will not have formal governance authority. From that point forward, progress toward settlement or trial will depend on the strength of the evidence and the parties’ incentives.
ImmunityBio and its executives will defend against the allegations, arguing that they did not misrepresent material facts or that any disclosures were adequate. The plaintiff’s counsel will argue the opposite—that the FDA warning letter’s severity should have been anticipated and disclosed, and that the 21% stock drop is evidence of the materiality of the undisclosed information. Settlement discussions often begin during the discovery phase (document exchanges and witness testimony). If no settlement is reached, the case may proceed to trial, though many securities cases resolve before trial.